Article

Monitoring Deamidation Progression in an Antibody Tryptic Digest using UPLC/MSE with BiopharmaLynx and a Xevo QTof MS - Waters Whitepaper

Monitoring Deamidation Progression in an Antibody Tryptic Digest using UPLC/MSE with BiopharmaLynx and a Xevo QTof MS - Waters Whitepaper

To view a PDF of this article from the BioPharm International archives, click this link

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Related Content
Cancer Cells test on laboratory test tube in the analyst's hand in a plastic glove | Image Credit: ©Giovanni Cancemi -stock.adobe.com
September 16th 2025

Biosynthetic Methods in Pharmaceutical Manufacturing

Cynthia A. Challener
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
September 16th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Destruction of lymphoblasts. Conceptual 3D illustration of treatment of acute lymphoblastic leukemia | Image Credit: © Dr_Microbe - stock.adobe.com
September 16th 2025

Gyala Therapeutics’ CAR-T Leukemia Therapy Shows Promise, Heads for Clinical Trial

Patrick Lavery
Mastering Antibody-Drug Conjugates
September 16th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Site Logo
September 16th 2025

Industrialize Autologous Therapies

Catalent
Drug manufacturing process. Conveyor with medical ampoules line at a modern pharmaceutical plant. Pharmacology production, medicine industry from laboratory 2 factory, pharmacy. Healthcare, pharma 3D | Image Credit: © Corona Borealis - © Corona Borealis - stock.adobe.com
September 16th 2025

PDA 2025: How Strategic CAPA Builds Anti-Fragile Manufacturing Compliance

Feliza Mirasol
© 2025 MJH Life Sciences

All rights reserved.